EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Amy S Paller iD, Loretta Fiorillo iD, Emily Becker, Susana Armesto iD, Apostolos Kontzias iD, Rajneet K Oberoi iD, Wendy Zhang, Hamid Amouzadeh, Zuoshun Zhang, Lisa Arkin iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf305 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Amy S Paller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Anti-Inflammatory Agents, Non-Steroidal, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral treatment options for paediatric patients with moderate-to-severe plaque psoriasis are limited. In the 16-week double-blind placebo-controlled phase of the SPROUT trial, apremilast demonstrated efficacy vs. placebo in paediatric patients with psoriasis.

Objectives

To evaluate the 52-week efficacy and safety of apremilast in SPROUT.

Methods

SPROUT was a phase III multicentre randomized double-blind placebo-controlled parallel-group study (NCT03701763). Patients were randomized 2 : 1 to receive apremilast 20 or 30 mg (for patients weighing 20 to < 50 kg or ≥ 50 kg at baseline, respectively) twice daily or placebo for 16 weeks, after which all patients received apremilast through week 52 (apremilast/apremilast or placebo/apremilast, respectively). Patients were aged 6–17 years and had moderate-to-severe psoriasis that was inadequately controlled by or intolerant to topical therapy.

Results

Of 245 patients randomized, 221 (apremilast/apremilast, n = 149; placebo/apremilast, n = 72) entered the apremilast extension phase and 186 (apremilast/apremilast, n = 125; placebo/apremilast, n = 61) completed 52 weeks. With continued apremilast treatment, rates of static Physician Global Assessment (sPGA) response (score of 0 or 1 with ≥ 2-point reduction from baseline) further improved from week 16 (30.1%) to week 52 (47.7%). In the placebo/apremilast group, sPGA response rates increased from 9.8% at week 16 to 44.4% at week 52. The proportions of patients with ≥ 75% reduction from baseline in Psoriasis Area and Severity Index increased from 42.3% at week 16 to 60.4% at week 52 in the apremilast/apremilast group and from 13.4% to 63.9% in the placebo/apremilast group. No new safety signals were observed.

Conclusions

Improvements in clinical outcomes were sustained through 52 weeks with apremilast treatment in paediatric patients with moderate-to-severe psoriasis. Safety findings were consistent with the known safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisThalidomideAnti-Inflammatory Agents, Non-SteroidalPhosphodiesterase 4 InhibitorsHumansChildMaleFemaleAdolescentDouble-Blind MethodTreatment OutcomeSeverity of Illness IndexAdministration, OralDose-Response Relationship, DrugDrug Administration Schedule

Substanzen

apremilastThalidomideAnti-Inflammatory Agents, Non-SteroidalPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA.
  • Stollery Children's Hospital University of Alberta, Edmonton, AB, Canada.
  • Driscoll Children's Hospital, Corpus Christi, TX, USA.
  • Hospital Universitario Marques de Valdecilla, Santander, Spain.
  • Amgen Inc., Thousand Oaks, CA, USA.
  • University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

ORCID-Profile: Amy S Paller, Loretta Fiorillo, Susana Armesto, Apostolos Kontzias, Rajneet K Oberoi, Lisa Arkin

Zitieren

APA

Paller, A. S., Fiorillo, L., Becker, E., Armesto, S., Kontzias, A., Oberoi, R. K., Zhang, W., Amouzadeh, H., Zhang, Z., & Arkin, L. (2025). Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf305

Vancouver

Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, et al. Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf305

BibTeX
@article{Paller2025,
  author = {Paller, Amy S and Fiorillo, Loretta and Becker, Emily and Armesto, Susana and Kontzias, Apostolos and Oberoi, Rajneet K and Zhang, Wendy and Amouzadeh, Hamid and Zhang, Zuoshun and Arkin, Lisa},
  title = {Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf305}
}
Kostenlos starten →